Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Robert Azelby is Director at Autolus Therapeutics. OQRO lists 5 transactions filed with the SEC under this name, the latest on Nov 16, 2026, each linked to the official Form 4.
Director
Disclosures on record
5
Companies involved
3
Robert Azelby has no open-market purchase on record since 2024. Sales in 1 of the 3 years since 2024.
Robert Azelby reported 0 open-market purchases and 1 sale since 2024; no open-market purchase.
| Year | Bought | Sold |
|---|---|---|
| 2024 | — | $20K1×1 trade |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Nov 12, 2026755disclosed Nov 16
DetailsOfficial recordAutolus TherapeuticsAUTL
2 disclosures · Jul 2026
Jun 29, 202632Kdisclosed Jul 1
DetailsOfficial recordJun 29, 202648Kdisclosed Jul 1
DetailsOfficial recordAdc TherapeuticsADCT
2 disclosures · Jun 2026
Jun 1, 202645Kdisclosed Jun 3
DetailsOfficial recordJun 3, 202613K
DetailsOfficial recordAs of the latest filing on , Robert Azelby reported holding 4,840 shares of Cardinal Health (CAH), worth about $1.32M at the last close of $273 (Nov 20, 2026). Holdings are also on file at Adc Therapeutics (ADCT); together they are worth about $1.46M.
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Cardinal Health CAH | 4,840 | 4,840 direct | $273 | $1.32M | Nov 12, 2026 |
| Adc Therapeutics ADCT | 112,805 | 113K direct | $1 | $144K | Jun 3, 2026 |
Is this Robert Azelby’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
On the latest SEC Form 4, dated Nov 12, 2026, Robert Azelby reported holding 4,840 shares of Cardinal Health (CAH). At the last close of $273 on Nov 20, 2026, that is about $1.32M. This is the stake disclosed in filings, not a net worth.
No public filing gives Robert Azelby's net worth. What SEC Form 4 shows is the stock stake: 4,840 shares of Cardinal Health (CAH), about $1.32M at the last close, plus holdings in 1 other company, about $1.46M in all. Cash, other investments, property, debts and unexercised options are not in these filings, so the real figure can be much higher or lower.
Robert Azelby has no open-market purchase on record since 2024. Sales in 1 of the 3 years since 2024.
In SEC filings since 2024: no open-market purchase is on record; the latest open-market sale is from 2024.
Adc Therapeutics (ADCT), from 2024 to 2024: 0 purchases and 1 sale.
Robert Azelby reported 0 open-market purchases and 1 sale here, 2024.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.